Improvements of Glucose and Lipid Metabolism After Jejuno-ileal Circuit Procedure in a Non-obese Diabetic Rat Model

This study was designed to investigate the influence of dietary chitosan feeding-duration on glucose and lipid metabolism in diabetic rats induced by streptozotocin and nicotinamide [a non-insulin-dependent diabetes mellitus (NIDDM) model]. Male Sprague-Dawley rats were used as experimental animals and divided into short-term (6 weeks) and long-term (11 weeks) feeding durations, and each duration contained five groups: (1) control, (2) control + 5% chitosan, (3) diabetes, (4) diabetes + 0.8 mg/kg rosiglitazone (a positive control), and (5) diabetes + 5% chitosan. Whether the chitosan feeding was for 6 or 11 weeks, the chitosan supplementation decreased blood glucose and lipids levels and liver lipid accumulation. However, chitosan supplementation decreased plasma tumor necrosis factor (TNF)-α, insulin levels, alanine aminotransferase (ALT) activity, insulin resistance (HOMA-IR), and adipose tissue lipoprotein lipase activity. Meanwhile, it increased plasma high-density lipoproteins (HDL)-cholesterol level, plasma angiopoietin-like-4 protein expression, and plasma triglyceride levels (at 11-week feeding duration only). Taken together, 11-week (long-term) chitosan feeding may help to ameliorate the glucose and lipid metabolism in a NIDDM diabetic rat model.

Download Full-text

Effects of Sleeve Gastrectomy on Lipid Metabolism in an Obese Diabetic Rat Model

Obesity Surgery ◽

10.1007/s11695-013-1035-7 ◽

2013 ◽

Vol 23 (12) ◽

pp. 1947-1956 ◽

Cited By ~ 17

Author(s):

Yuichiro Kawano ◽

Masayuki Ohta ◽

Teijiro Hirashita ◽

Takashi Masuda ◽

Masafumi Inomata ◽

...

Keyword(s):

Sleeve Gastrectomy ◽

Lipid Metabolism ◽

Rat Model ◽

Diabetic Rat ◽

Diabetic Rat Model

Download Full-text

Absence of propolis effect on plasma glycaemic control and lipid metabolism in a diabetic rat model.

Journal of ApiProduct and ApiMedical Science ◽

10.3896/ibra.4.01.2.05 ◽

2009 ◽

Vol 1 (2) ◽

pp. 51-55 ◽

Cited By ~ 3

Author(s):

José M. Sforcin

Keyword(s):

Lipid Metabolism ◽

Glycaemic Control ◽

Rat Model ◽

Diabetic Rat ◽

Diabetic Rat Model

Download Full-text

Pomegranate flower improves cardiac lipid metabolism in a diabetic rat model: role of lowering circulating lipids

British Journal of Pharmacology ◽

10.1038/sj.bjp.0706245 ◽

2005 ◽

Vol 145 (6) ◽

pp. 767-774 ◽

Cited By ~ 80

Author(s):

Tom Hsun-Wei Huang ◽

Gang Peng ◽

Bhavani Prasad Kota ◽

George Qian Li ◽

Johji Yamahara ◽

...

Keyword(s):

Lipid Metabolism ◽

Rat Model ◽

Diabetic Rat ◽

Cardiac Lipid ◽

Diabetic Rat Model

Download Full-text

Adenovirus-mediated expression of SIK1 improves hepatic glucose and lipid metabolism in type 2 diabetes mellitus rats

10.1101/514299 ◽

2019 ◽

Author(s):

DaoFei Song ◽

Lei Yin ◽

Chang Wang ◽

XiuYing Wen

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Lipid Metabolism ◽

Rat Model ◽

Diabetic Rat ◽

Glucose And Lipid Metabolism ◽

Hepatic Glucose ◽

Element Binding Protein

AbstractAIMIn this study, we investigated the role and mechanism of Salt-induced kinase 1 (SIK1) in regulation of hepatic glucose and lipid metabolism in a high-fat food (HFD) and streptozocin (STZ)-induced type 2 diabetes mellitus (T2DM) rat model.MethodsA diabetic rat model treated with HFD plus low-dose STZ was developed and was transduced to induce a high expression of SIK1 in vivo via a tail-vein injection of a recombinant adenoviral vector. The effects on hepatic glucogenetic and lipogenic gene expression, systemic metabolism and pathological changes were then determined.ResultsIn T2DM rats, SIK1 expression was reduced in the liver. Overexpression of SIK1 improved hyperglycaemia, hyperlipidaemia and fatty liver, reduced the expression of cAMP-response element binding protein (CREB)-regulated transcription co-activator 2 (CRTC2), phosphoenolpyruvate carboxykinase (PEPCK), glucose-6-phosphatase (G6Pase), pS577 SIK1, sterol regulatory element binding-protein-1c (SREBP-1c) and its target genes, including acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS), and increased the expression of SIK1, pT182 SIK1 and pS171 CRTC2 in diabetic rat livers with the suppression of gluconeogenesis and lipid deposition.ConclusionSIK1 plays a crucial role in the regulation of glucose and lipid metabolism in the livers of HFD/STZ-induced T2DM rats, where it suppresses hepatic gluconeogenesis and lipogenesis by regulating the SIK1/CRTC2 and SIK1/SREBP-1c signalling pathways. Strategies to activate SIK1 kinase in liver would likely have beneficial effects in patients with T2DM and nonalcoholic fatty liver disease (NAFLD).

Download Full-text

Exploration of the Effect and Mechanism of ShenQi Compound in a Spontaneous Diabetic Rat Model

Endocrine Metabolic & Immune Disorders - Drug Targets ◽

10.2174/1871530319666190225113859 ◽

2019 ◽

Vol 19 (5) ◽

pp. 622-631 ◽

Cited By ~ 3

Author(s):

Ya Liu ◽

Jian Kang ◽

Hong Gao ◽

Xiyu Zhang ◽

Jun Chao ◽

...

Keyword(s):

Blood Glucose ◽

Signaling Pathway ◽

Rat Model ◽

Mtor Signaling ◽

Diabetic Rat ◽

Gene Microarray ◽

Mtor Signaling Pathway ◽

Glucose Fluctuation ◽

Blood Glucose Fluctuation ◽

Diabetic Rat Model

Background: Type 2 Diabetes Mellitus (T2DM) is a world-wide metabolic disease with no cure from drugs and treatment. In China, The Traditional Chinese Medicine (TCM) herbal formulations have been used to treat T2DM for centuries. Methods: In this study, we proposed a formula called ShenQi Compound (SQC), which has been used in clinical therapeutics in China for several years. We evaluated the effect of SQC in a spontaneous diabetic rat model (GK rats) by detecting a series of blood indicators and performing histological observations. Meanwhile, the gene microarray and RT-qPCR experiments were used to explore the molecular mechanism of SQC treatment. In addition, western medicine, sitagliptin was employed as a comparison. Results: The results indicated that SQC and sitagliptin could effectively improve the serum lipid (blood Total Cholesterol (TC) and blood Triglycerides (TG)), hormone levels (serum insulin (INS), Glucagon (GC) and Glucagon-Like Peptide-1 (GLP-1)), alleviated the inflammatory response (hypersensitive C-Reactive Protein (hsCRP)), blood glucose fluctuation (Mean Blood Glucose (MBG), standard deviation of blood glucose (SDBG) and Largest Amplitude of plasma Glucose Excursions (LAGE)), pancreatic tissue damage and vascular injury for T2DM. Compared with sitagliptin, SQC achieved a better effect on blood glucose fluctuation (p<0.01). Meanwhile, the gene microarray and RT-qPCR experiments indicated that SQC and sitagliptin may improve the T2DM through affecting the biological functions related to apoptosis and circadian rhythm. Moreover, SQC might be able to influence the mTOR signaling pathway by regulating Pik3r1, Ddit4 expression. Conclusion: All these results indicate that SQC is an effective therapeutic drug on T2DM. Notably, SQC presents an obvious blood glucose fluctuation-preventing ability, which might be derived from the regulation of the mTOR signaling pathway.

Download Full-text